Mishima, K <br/><br/>
Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.  [electronic resource] 

 -  Cancer research  Jul 2001 
 - 5349-54 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Brain Neoplasms--drug therapy<br/>Cell Division--drug effects<br/>Down-Regulation--drug effects<br/>ErbB Receptors--genetics<br/>Gene Expression Regulation, Neoplastic<br/>Glioblastoma--drug therapy<br/>Humans<br/>In Situ Nick-End Labeling<br/>Mice<br/>Mice, Nude<br/>Mutation<br/>Neovascularization, Pathologic--prevention & control<br/>Phosphorylation--drug effects<br/>Proto-Oncogene Proteins c-bcl-2--drug effects<br/>Survival Analysis<br/>Survival Rate<br/>Transplantation, Heterologous<br/>Treatment Outcome<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays<br/>bcl-X Protein